E. A. Gridneva
E. A. Gridneva has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Ismailova
Republic of Dagestan Republican Clinical Hospital of Emergency Medical Care, Makhachkala
1 shared publication - A. A. Ispiriyan
Voronezh City Clinical Hospital №3, Voronezh
1 shared publication - A. N. Savenkova
Voronezh City Clinical Hospital № 3, Voronezh
1 shared publication - E. H. Melnikova
Central City Hospital, Azov
1 shared publication - F. R. Khaidarova
Clinical Hospital for War Veterans, Grozny
1 shared publication - Irina A. Cheremisina
OOO Alfasigma Rus
1 shared publication
Latest Publications
- Open Access
- 31 July 2021
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 61 (7) , 22-27
Interim Results of the BYHEART Observational Study: Exogenous Phosphocreatine Effect on the Quality of life of Patients with Chronic Heart Failure
Aim Improvement of quality of life is one of the most important goals for the treatment of patients with chronic heart failure (CHF). This study searched for ways to increase the efficiency of CHF treatment based on parameters of quality of life in CHF patients during and after the treatment with exogenous phosphocreatine (EP). Material and methods The effect of a single course of EP treatment on quality of life of patients with functional class (FC) II-IV CHF with reduced or mid-range left ventricular ejection fraction was studied as a part of the all-Russia prospective observational study BYHEART. The presence of FC II-IV CHF and a left ventricular ejection fraction Results An interim data analysis showed that the course of EP treatment was associated with a significant improvement of quality-of-life indexes as determined by the Minnesota Living with Heart Failure Questionnaire (LHFQ) total score. These indexes significantly increased and remained at a satisfactory level for 6 mos. following completion of the treatment course. Also, the treatment significantly beneficially influenced the clinical condition of patients (heart failure severity scale), results of 6MWT, and the increase in left ventricular ejection fraction. Conclusion The conclusions based on results of the interim analysis should be confirmed by results of the completed study. Complete results are planned to be published in 2022.
- 31 July 2021
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 61 (7) , 22-27
Open AccessInterim Results of the BYHEART Observational Study: Exogenous Phosphocreatine Effect on the Quality of life of Patients with Chronic Heart Failure
Aim Improvement of quality of life is one of the most important goals for the treatment of patients with chronic heart failure (CHF). This study searched for ways to increase the efficiency of CHF treatment based on parameters of quality of life in CHF patients during and after the treatment with exogenous phosphocreatine (EP). Material and methods The effect of a single course of EP treatment on quality of life of patients with functional class (FC) II-IV CHF with reduced or mid-range left ventricular ejection fraction was studied as a part of the all-Russia prospective observational study BYHEART. The presence of FC II-IV CHF and a left ventricular ejection fraction Results An interim data analysis showed that the course of EP treatment was associated with a significant improvement of quality-of-life indexes as determined by the Minnesota Living with Heart Failure Questionnaire (LHFQ) total score. These indexes significantly increased and remained at a satisfactory level for 6 mos. following completion of the treatment course. Also, the treatment significantly beneficially influenced the clinical condition of patients (heart failure severity scale), results of 6MWT, and the increase in left ventricular ejection fraction. Conclusion The conclusions based on results of the interim analysis should be confirmed by results of the completed study. Complete results are planned to be published in 2022.